AlphAIAlphAI — Financial news for AI agents
thepharmaletter.comOCT 62 min read$ABBV

Genmab and AbbVie tout Phase III results for epcoritamab in DLBCL

AbbVie (ABBV) and Genmab (GMAB) reported positive Phase III trial results for epcoritamab in DLBCL patients. The treatment, combined with standard care, showed promise in newly diagnosed cases with IPI scores of 2 to 5.

Original reporting
thepharmaletter.com
Published Oct 6, 2026, 11:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 1:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Genmab and AbbVie tout Phase III results for epcoritamab in DLBCL — source image
Source · thepharmaletter.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The data represent a pivotal step toward FDA submission, enhancing both companies' pipelines and market valuations.

02

Market read

First‑report positive Phase III results are likely to drive immediate buying interest in both stocks and lift the broader oncology biotech sector.

03

What to watch

Potential competition from other bispecifics and the need for FDA filing timelines may temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Phase III EPCORE DLBCL-2 trial evaluated epcoritamab with R‑CHOP in newly diagnosed diffuse large B‑cell lymphoma patients.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie announced positive Phase III epcoritamab data in DLBCL, a first‑report clinical trial result.

Expected impact

upward pressure as market prices in potential regulatory approval and revenue uplift.

Evidence & confidence

Phase III success is material for a large pharma; investors typically bid up stocks on such news.

$GMABBullishHigh confidence
Context

Genmab co‑reported the same positive Phase III epcoritamab results for DLBCL.

Expected impact

upward pressure as the market values the partnership and upcoming commercialization potential.

Evidence & confidence

Positive pivotal data and a major US partner are strong catalysts for a biotech.

Market effects

Sector

Boosts the oncology biotech sector and may lift peers developing bispecific antibodies.

Regional

Positive for US and European pharma markets, especially US-listed biotech stocks.

Global

Adds optimism to global cancer‑therapy pipelines, potentially influencing investor sentiment worldwide.

Counterpoint

What could challenge this read

If regulatory hurdles or safety concerns emerge, the initial rally could reverse quickly.

Key entities

  • company
    AbbVie

    US pharma major, ticker ABBV.

  • company
    Genmab

    Denmark‑based biotech, ticker GMAB.

Read at source← All news

Also covered by

4 outlets

Related articles

OCT 6
$ABBVMed

AbbVie Stocks Edge Higher as Lymphoma Trial Cuts Progression Risk 51%

AbbVie (ABBV) shares rose 0.3% to $266.63 on Oct. 6 after a late-stage trial showed its blood-cancer treatment, epcoritamab plus R-CHOP, reduced the risk of disease progression or death by 51% compared to R-CHOP alone in diffuse large B-cell lymphoma. The trial's hazard ratio was 0.49, with a p-value below 0.0001, and safety was consistent with known profiles.

finance.yahoo.com2 min
OCT 6
$ABBVHighAI 9/10

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

AbbVie (ABBV) and Genmab (GMAB) reported positive phase III trial results for epcoritamab combined with R-CHOP in frontline DLBCL, showing a 51% reduction in disease progression or death. The study met its primary endpoint, and the combo was well-tolerated. Both companies plan regulatory discussions. AbbVie's shares are up 19.1% YTD. Epcoritamab is approved as a monotherapy in several regions.

theglobeandmail.com2 min
OCT 6
$ABBVHighAI 9/10

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

Genmab and AbbVie's Epkinly, combined with chemotherapy, reduced disease progression or death risk by 51% in a Phase 3 lymphoma trial. The results exceeded expectations and could boost Epkinly's sales. Genmab reported $312M in Epkinly sales in H1 2024, and its shares rose 14% on the news. Epkinly may become the first drug of its kind approved for first-line DLBCL.

finance.yahoo.com2 min
OCT 6
$ABBVMed

AbbVie and Genmab Report 51% Reduction in Progression With Epcoritamab Plus R-CHOP in Diffuse Large B-cell Lymphoma

AbbVie and Genmab reported Phase 3 trial results showing a 51% reduction in disease progression or death for epcoritamab plus R-CHOP in diffuse large B-cell lymphoma (DLBCL) patients with IPI scores of 2-5. The combination therapy met its primary endpoint, improving progression-free survival. The companies plan to discuss the findings with regulators. Epcoritamab is an investigational bispecific antibody.

oncodaily.com2 min